Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study

被引：23

作者：

Almeida, Antonio M. ^{[1
]}

Prebet, Thomas ^{[2
,3
]}

Itzykson, Raphael ^{[4
]}

Ramos, Fernando ^{[5
]}

Al-Ali, Haifa ^{[6
]}

Shammo, Jamile ^{[7
]}

Pinto, Ricardo ^{[8
]}

Maurillo, Luca ^{[9
]}

Wetzel, Jaime ^{[10
]}

Musto, Pellegrino ^{[11
]}

Van De Loosdrecht, Arjan A. ^{[12
]}

Costa, Maria Joao ^{[13
]}

Esteves, Susana ^{[1
]}

Burgstaller, Sonja ^{[14
]}

Stauder, Reinhard ^{[15
]}

Autzinger, Eva M. ^{[16
]}

Lang, Alois ^{[17
]}

Krippl, Peter ^{[18
]}

Geissler, Dietmar ^{[19
]}

Francisco Falantes, Jose ^{[20
]}

Pedro, Carmen ^{[21
]}

Bargay, Joan ^{[22
]}

Deben, Guillermo ^{[23
]}

Garrido, Ana ^{[24
]}

Bonanad, Santiago ^{[25
]}

Diez-Campelo, Maria ^{[26
]}

Thepot, Sylvain ^{[27
]}

Ades, Lionel ^{[4
]}

Sperr, Wolfgang R. ^{[28
,29
]}

Valent, Peter ^{[28
,29
]}

Fenaux, Pierre ^{[4
]}

Sekeres, Mikkael A. ^{[10
]}

Greil, Richard ^{[30
,31
,32
,33
]}

Pleyer, Lisa ^{[30
,31
,32
,33
]}

机构：

[1] IPOL, P-1200795 Lisbon, Portugal

[2] Inst Paoli Calmettes, Marseille, France

[3] Yale New Haven Med Ctr, New Haven, CT 06512 USA

[4] Paris Diderot Univ, Hop St Louis, AP HP, F-75010 Paris, France

[5] Hosp Univ Leon, Leon 24071, Spain

[6] Univ Hosp Halle, D-06120 Halle, Germany

[7] Rush Univ, Med Ctr, Chicago, IN 60612 USA

[8] Hosp Sao Joao, P-4200319 Oporto, Portugal

[9] Univ Tor Vergata, I-00173 Rome, Italy

[10] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44195 USA

[11] Referral Canc Ctr Basilicata, RCCS CROB, I-85028 Rionero In Vulture, Pz, Italy

[12] Vrije Univ Amsterdam, Med Ctr, Dept Hematol, NL-1081 HV Amsterdam, Netherlands

[13] Hosp Santa Maria, Ctr Hosp Lisboa Norte, P-1649035 Lisbon, Portugal

[14] Hosp Wels Grieskirchen, Dept Internal Med 4, A-4600 Wels, Austria

[15] Innsbruck Med Univ, Dept Internal Med Haematol & Oncol 5, A-6020 Innsbruck, Austria

[16] Wilhelminenspital Stadt Wien, Ctr Oncol & Hematol, Dept Internal Med 1, A-1160 Vienna, Austria

[17] Hosp Feldkirch, Internal Med, A-6800 Feldkirch, Austria

[18] Hosp Furstenfeld, Dept Internal Med, A-8280 Furstenfeld, Austria

[19] Klinikum Klagenfurt Worthersee, Dept Internal Med, A-9020 Portschach Am Worthersee, Austria

[20] Hosp Univ Virgen Rocio, Seville 41013, Spain

[21] Hosp Mar, Barcelona 08003, Spain

[22] Hosp Son Llatzer, Palma De Mallorca 07198, Spain

[23] Hosp Univ, La Coruna 15006, Spain

[24] Hosp Santa Creu & Sant Pau, Barcelona 08026, Spain

[25] Hosp Univ Ribera, Alzira 46600, Spain

[26] Hosp Univ Salamanca, Salamanca 37007, Spain

[27] CHU, F-49100 Angers, France

[28] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria

[29] Med Univ Vienna, Ludwig Boltzmann Cluster Oncol, A-1090 Vienna, Austria

[30] Paracelsus Med Univ, Med Dept 3, A-5020 Salzburg, Austria

[31] Salzburg Canc Res Inst, A-5020 Salzburg, Austria

[32] Canc Cluster Salzburg, A-5020 Salzburg, Austria

[33] Arbeitsgemeinschaft Medikamentose Tumortherapie A, A-5020 Salzburg, Austria

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2017年 / 18卷 / 04期

关键词：

acute erythroleukemia; azacitidine; decitabine; ACUTE MYELOID-LEUKEMIA; CONVENTIONAL CARE REGIMENS; ACUTE ERYTHROID LEUKEMIA; HEALTH-ORGANIZATION CLASSIFICATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; STEM-CELL TRANSPLANTATION; MYELODYSPLASTIC SYNDROMES; OLDER PATIENTS; OPEN-LABEL; COMPLETE REMISSION;

D O I：

10.3390/ijms18040837

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p <= 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.

引用

页数：16

共 63 条

[1]

Almeida Antonio, 2017, Leuk Res Rep, V7, P6, DOI 10.1016/j.lrr.2016.12.002

[2] Decitabine (5-Aza-2′-deoxycytidine) decreased DNA methylation and expression of MDR-1 gene in K562/ADM cells [J].

Ando, T ;

Nishimura, M ;

Oka, Y .

LEUKEMIA, 2000, 14 (11) :1915-1920

[3] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia [J].

Arber, Daniel A. ;

Orazi, Attilio ;

Hasserjian, Robert ;

Thiele, Jurgen ;

Borowitz, Michael J. ;

Le Beau, Michelle M. ;

Bloomfield, Clara D. ;

Cazzola, Mario ;

Vardiman, James W. .

BLOOD, 2016, 127 (20) :2391-2405

[4] Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes [J].

Arenillas, Leonor ;

Calvo, Xavier ;

Luno, Elisa ;

Senent, Leonor ;

Alonso, Esther ;

Ramos, Fernando ;

Teresa Ardanaz, Maria ;

Pedro, Carme ;

Tormo, Mar ;

Marco, Victor ;

Montoro, Julia ;

Diez-Campelo, Maria ;

Brunet, Salut ;

Arrizabalaga, Beatriz ;

Xicoy, Blanca ;

Andreu, Rafael ;

Bonanad, Santiago ;

Jerez, Andres ;

Nomdedeu, Benet ;

Ferrer, Ana ;

Sanz, Guillermo F. ;

Florensa, Lourdes .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (27) :3284-+

[5] ERYTHROLEUKEMIA - A REVIEW OF 15 CASES MEETING 1985 FAB CRITERIA AND SURVEY OF THE LITERATURE [J].

ATKINSON, J ;

HRISINKO, MA ;

WEIL, SC .

BLOOD REVIEWS, 1992, 6 (04) :204-214

[6] Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes [J].

Calvo, Xavier ;

Arenillas, Leonor ;

Luno, Elisa ;

Senent, Leonor ;

Arnan, Montserrat ;

Ramos, Fernando ;

Teresa Ardanaz, Maria ;

Pedro, Carme ;

Tormo, Mar ;

Montoro, Julia ;

Diez-Campelo, Maria ;

Arrizabalagall, Beatriz ;

Xicoy, Blanca ;

Bonanad, Santiago ;

Jerez, Andres ;

Nomdedeu, Benet ;

Ferrer, Ana ;

Sanz, Guillermo F. ;

Florensa, Lourdes .

MODERN PATHOLOGY, 2016, 29 (12) :1541-1551

[7]

Camera A, 2002, HAEMATOLOGICA, V87, P1225

[8] Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia [J].

Cheson, Bruce D. ;

Greenberg, Peter L. ;

Bennett, John M. ;

Lowenberg, Bob ;

Wijermans, Pierre W. ;

Nimer, Stephen D. ;

Pinto, Antonio ;

Beran, Miloslav ;

de Witte, Theo M. ;

Stone, Richard M. ;

Mittelman, Moshe ;

Sanz, Guillermo F. ;

Gore, Steven D. ;

Schiffer, Charles A. ;

Kantarjian, Hagop .

BLOOD, 2006, 108 (02) :419-425

[9] Prognostic factors and treatment effects on survival in acute myeloid leukemia of M6 subtype: A retrospective study of 54 cases [J].

Colita, A ;

Belhabri, A ;

Chelghoum, Y ;

Charrin, C ;

Fiere, D ;

Thomas, X .

ANNALS OF ONCOLOGY, 2001, 12 (04) :451-455

[10]

CREUSOT F, 1982, J BIOL CHEM, V257, P2041

← 1 2 3 4 5 6 7 →